DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lac-Hydrin (Ammonium Lactate Topical) - Summary

 
 



LAC-HYDRIN SUMMARY

Lac-Hydrin® (ammonium lactate) Lotion 12%

Lac-Hydrin specially formulates 12% lactic acid, neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.4-5.5.

Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.


See all Lac-Hydrin indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Lac-Hydrin (Ammonium Lactate Topical)

A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. [2009.12]
Atopic dermatitis (AD) is a common chronic skin disease, which mainly affects children... The liquid soap was found to be effective in patients with AD, as use of this soap in patients with stable mild to moderate AD improved the parameters studied.

An evaluation of the moisturizing and anti-itch effects of a lactic acid and pramoxine hydrochloride cream. [2004.02]
An open-label, single-center, observer-blinded, controlled trial was conducted during the winter months to evaluate the moisturizing and antipruritic effects of a unique formulation of lactic acid 12% neutralized with ammonium hydroxide and pramoxine hydrochloride (HCl) 1% in 24 women with a history of dry itchy skin...

A double-blind clinical trial comparing the efficacy and safety of pure lanolin versus ammonium lactate 12% cream for the treatment of moderate to severe foot xerosis. [2003.01]
Xerotic skin is a pattern of reaction to a variety of disorders (eg, winter xerosis, hereditary ichthyosis) with abnormalities of desquamation in common. The trial described in this article was a double-blind randomized-comparison clinical trial investigating the effect of pure lanolin versus ammonium lactate 12% cream in treating moderate to severe foot xerosis...

A comparative study of lactic acid 10% and ammonium lactate 12% lotion in the treatment of foot xerosis. [2002.03]
Xerotic skin is a pattern of reaction to a variety of disorders that have abnormalities of desquamation in common. This double-blind, randomized clinical trial investigated the effect of Lactinol (Pedinol Pharmaceuticals, Farmingdale, New York) versus Lac-Hydrin 12% (Bristol-Myers Squibb, Princeton, New Jersey) lotion in mild to moderate foot xerosis...

Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. [2002]
BACKGROUND: Urea and ammonium lactate are used for the treatment of xerosis, with different degrees of success. This study compares the clinical effectiveness of these two agents... DISCUSSION: At day 14 of treatment, 40% urea cream was superior to 12% ammonium lactate for most of the instrumental and clinical assessments.

more studies >>

Clinical Trials Related to Lac-Hydrin (Ammonium Lactate Topical)

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis [Completed]
This is an investigator-masked, randomized, parallel, clinical study comparing the efficacy of once daily versus twice daily application of Ultravate® ointment (halobetasol propionate 0. 05% ointment) in combination with Lac-Hydrin lotion (ammonium lactate topical) in the treatment of stable plaque psoriasis. 1) Phase 1: Patients will be treated for two weeks with combination therapy using Ultravate® ointment with Lac-Hydrin lotion and their psoriasis plaques will be evaluated to test efficacy of the medication. Half the subjects will be randomized to receive treatment with once a day UltravateĀ® ointment and twice daily Lac-Hydrin lotion; the other half of subjects will receive twice daily UltravateĀ® ointment with twice daily Lac-Hydrin lotion. UltravateĀ® ointment will be discontinued following two weeks of treatment, in compliance with its FDA indication. Phase 2: The second treatment phase will consist of a four-week observation period. Subjects will be re-randomized to either continue using twice daily Lac-Hydrin lotion, versus no treatment. The purpose of this second phase of the study is to investigate whether use of Lac-Hydrin monotherapy twice daily can minimize risk of recurrence and maximize duration of therapeutic effect. Part of this clinical study consists of the use of patient and physician satisfaction questionnaires. These questionnaires will include questions about the satisfaction with the formulation of each agent, questions about compliance with treatment, etc. Such questions could be used to demonstrate patient and physician satisfaction with each agent, with combination therapy, and to compare patient satisfaction rates among those randomized to once daily versus twice daily application of UltravateĀ® ointment. The hypothesis is that Ultravate ointment once daily in combination with Lac-Hydrin twice daily is equal in efficacy to Ultravate ointment twice daily in combination with Lac-Hydrin twice daily.

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis [Completed]
The purpose of this study is to determine whether the combinational use of ammonium lactate lotion 12% (Lac-Hydrin) and halobetasol propionate ointment 0. 05% (Ultravate) is safe and effective in the initial treatment and long-term maintenance of psoriasis. Patients will use both medications continuously for two weeks and those who obtain a good improvement based on investigator clinical assessments will be randomized to Lac-Hydrin lotion twice daily every day with placebo ointment or Ultravate ointment twice daily on weekends only for up to 24 more weeks.

Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) [Active, not recruiting]
Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are among the leading causes of pediatric hospitalization in Asia. Mortality rates range from 1% at centres experienced in fluid resuscitation, to upto 44% in established shock. The mainstay of DSS treatment is prompt, vigorous fluid resuscitation with isotonic crystalloid solutions, followed by plasma or colloid solutions for profound or continuing shock. However, this administration is often associated with fluid overload and induces edema in these patients. Hence, we planned a parallel, randomized controlled trial comparing the efficacy and safety of solution containing half molar sodium lactate (Totilacā„¢) with standard treatment(isotonic crystalloid Ringer's Lactate) in pediatric Dengue Shock Syndrome patients, using plasma soluble Vascular Cell Adhesion Molecule(sVCAM-1) levels as an indicator. Hypertonic solutions restore hemodynamic status rapidly with increased cardiac performance and improved tissue perfusion. This is obtained with much smaller volumes. We plan to assess the efficacy and safety of hypertonic sodium lactate in resuscitation of DHF/DSS patients.

Continuous MONItoring of Blood LActate and Glucose Levels Using a New Central Veinous Microdialysis Catheter Device [Recruiting]

0.5M Na Lactate Solution in Acute Heart Failure (AHF) [Completed]
The objective of this trial to see whether:

- Cardiac performance (cardiac index and secondary outcomes)can be improved in patients with

acute heart failure (AHF) and symptoms and consequences of fluid overload (pulmonary and interstitial edema) and poor peripheral perfusion can be reduced by: 1. Providing lactate as a substrate(Improve cardiac index) 2. Simultaneously restoring optimal preload Optimal standard treatment will be achieved in both arms with the use of current best treatment protocol for AHF as per independent treating physician. 4. To assess effects of 0. 5M Na lactate (Totilac) on plasma and urine biological parameters (sodium, potassium, chloride, pH, bicarb, base excess, albumin) 5. To assess effects of 0. 5M Na lactate on morbidity and mortality.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, LAC-Hydrin has an overall score of 5. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

LAC-Hydrin review by 31 year old male patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Extremely dry skin
Dosage & duration:   12% (dosage frequency: twice daily) for the period of 6 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   It was helpful in reducing the severity on my life-long extremely dry, flaky, itchy skin. It was recommended that I be certain to apply it directly after a shower, when the skin still retains some of it's moisture from the shower itself. This is true for all lotions, but seemed particularly helpful with the Lac-hydrin. Unfortunately, though it was more helpful than many lotions I've used, the benefits did not warrant the higher price of the product. Ultimately, I've found BETTER results with the much cheaper Eucerin and even Curel moisturizing lines.
Side effects:   During the 6 months during which I used the Lac-hydrin, I didn't experience any negative side-effects. I was using it during winter months, so I don't have any feedback to offer on sun-sensitivity. I didn't experience any additional skin irritation that lessened my interest in the product. I simply moved on to other products because of the price.
Comments:   The Lac-hydrin was applied topically to all parts of my body (expect my face) twice daily. My dermatologist recommended that one of the applications be directly after my shower. The skin will retain moisture from the shower for a bit, and the application of the Lac-hydrin will help to keep it there. I would reapply to dry skin again before bed.

See all LAC-Hydrin reviews / ratings >>

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015